00:17 , Jun 27, 2019 |  BC Extra  |  Company News

With $104M series C debut, Encoded takes on expansion of gene therapies

Encoded wants to fine-tune expression of gene therapies, and expand the indications and targets for which they can be used, taking the technology beyond the limits set by payload size. Emerging from stealth with a...
12:31 , Jun 13, 2019 |  BioCentury  |  Finance

With $76M series B, BlackThorn looks to build out neurobehavioral platform

BlackThorn has amassed a $76 million series B round from investors who are banking on the potential of its PathFinder platform to circumvent the issue of patient heterogeneity in neurobehavioral disorders. New investors Polaris Partners,...
10:08 , Apr 30, 2019 |  BioCentury  |  Finance

How Nextech-led round will help Vividion to POC

After identifying three lead programs with its proteome-wide small molecule screening platform, San Diego-based Vividion has raised $82 million in an oversubscribed series B round led by new investor Nextech Invest. Now flush with over...
17:33 , Mar 8, 2019 |  BC Week In Review  |  Financial News

Beam raises $135M series B

By raising a $135 million series B round on Wednesday, base editing company Beam Therapeutics has surpassed CRISPR Therapeutics AG (NASDAQ:CRSP) for the most venture money raised by a CRISPR-based company. Added to its May...
12:11 , Mar 6, 2019 |  BioCentury  |  Finance

Beam broadens base with $135M B round

By raising a $135 million series B round on Wednesday, base editing company Beam Therapeutics has surpassed CRISPR Therapeutics AG (NASDAQ:CRSP) for the most venture money raised by a CRISPR-based company. Added to its May...
18:33 , Dec 14, 2018 |  BC Week In Review  |  Company News

Millendo, OvaScience merge, raise $50M

Emerging from the reverse-merger of private endocrine company Millendo Therapeutics Inc. and former public fertility company OvaScience Inc., Millendo Therapeutics Inc. (NASDAQ:MLND) raised $49.5 million in a financing Friday. The combined company will begin trading...
17:50 , Dec 7, 2018 |  BC Extra  |  Company News

Millendo, OvaScience merge, raise $50M

Emerging from the reverse-merger of private endocrine company Millendo Therapeutics Inc. and former public fertility company OvaScience Inc., Millendo Therapeutics Inc. (NASDAQ:MLND) raised $49.5 million in a financing Friday. The combined company will begin trading...
06:12 , Aug 10, 2018 |  BC Week In Review  |  Company News

Millendo, OvaScience reverse merging

Fertility company OvaScience Inc. (NASDAQ:OVAS) will reverse-merge with endocrine play Millendo Therapeutics Inc. (Ann Arbor, Mich.) in an all-stock deal. The resulting company will focus on developing Millendo's pipeline for orphan indications. New Enterprise Associates,...
17:17 , Aug 3, 2018 |  BC Week In Review  |  Financial News

Omniome raises $60M series B

DNA sequencing company Omniome Inc. (San Diego, Calif.) raised $60 million on July 30 in a series B round led by new investors Decheng Capital and Hillhouse Capital Group. New investors Lam Research Capital and...
00:24 , Aug 3, 2018 |  BioCentury  |  Finance

Appetite for Omniome

An experienced team and a growing DNA sequencing market in China enabled San Diego’s Omniome Inc. to raise a $60 million series B round led by Chinese investors. Decheng Capital and Hillhouse Capital Group co-led...